MXPA05003161A - Uso de derivados de 4-piridil-metil-ftalazina para la fabricacion de un medicamento para el tratamiento de sindromes mielodisplasticos. - Google Patents
Uso de derivados de 4-piridil-metil-ftalazina para la fabricacion de un medicamento para el tratamiento de sindromes mielodisplasticos.Info
- Publication number
- MXPA05003161A MXPA05003161A MXPA05003161A MXPA05003161A MXPA05003161A MX PA05003161 A MXPA05003161 A MX PA05003161A MX PA05003161 A MXPA05003161 A MX PA05003161A MX PA05003161 A MXPA05003161 A MX PA05003161A MX PA05003161 A MXPA05003161 A MX PA05003161A
- Authority
- MX
- Mexico
- Prior art keywords
- combination
- pyridyl
- vitamin
- treatment
- myelodysplastic syndromes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41317602P | 2002-09-24 | 2002-09-24 | |
| PCT/EP2003/010578 WO2004028542A1 (en) | 2002-09-24 | 2003-09-23 | Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05003161A true MXPA05003161A (es) | 2005-09-12 |
Family
ID=32043216
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05003161A MXPA05003161A (es) | 2002-09-24 | 2003-09-23 | Uso de derivados de 4-piridil-metil-ftalazina para la fabricacion de un medicamento para el tratamiento de sindromes mielodisplasticos. |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20060128716A1 (enExample) |
| EP (1) | EP1545534B1 (enExample) |
| JP (1) | JP2006502195A (enExample) |
| KR (1) | KR20050074450A (enExample) |
| CN (1) | CN100372535C (enExample) |
| AT (1) | ATE359789T1 (enExample) |
| AU (1) | AU2003299065B2 (enExample) |
| BR (1) | BR0314647A (enExample) |
| CA (1) | CA2499738A1 (enExample) |
| CR (1) | CR7754A (enExample) |
| DE (1) | DE60313344T2 (enExample) |
| EC (1) | ECSP055700A (enExample) |
| ES (1) | ES2285251T3 (enExample) |
| HR (1) | HRP20050281A2 (enExample) |
| MX (1) | MXPA05003161A (enExample) |
| NO (1) | NO20051936L (enExample) |
| PL (1) | PL374696A1 (enExample) |
| PT (1) | PT1545534E (enExample) |
| RS (1) | RS20050228A (enExample) |
| RU (1) | RU2353364C2 (enExample) |
| WO (1) | WO2004028542A1 (enExample) |
| ZA (1) | ZA200502212B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1391206B1 (en) * | 1997-10-15 | 2008-07-02 | Polarx Biopharmaceuticals, Inc. | Pharmaceutical compositions comprising arsenic trioxide for the treatment of non-Hodgkin's lymphoma |
| US7915410B2 (en) | 2005-09-09 | 2011-03-29 | Bristol-Myers Squibb Company | Acyclic IKur inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7132458B2 (en) * | 1994-08-10 | 2006-11-07 | Chemaphor Inc. | Oxidized carotenoid fractions and ketoaldehyde useful as cell-differentiation inducers, cytostatic agents, and anti-tumor agents |
| IL115156A (en) * | 1994-09-06 | 2000-07-16 | Univ Georgia | Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines |
| RU2136308C1 (ru) * | 1994-11-16 | 1999-09-10 | Жемчугов Владислав Евгеньевич | Стимулятор роста костно-мозговых клеток человека |
| CO4950519A1 (es) * | 1997-02-13 | 2000-09-01 | Novartis Ag | Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion |
| ATE329596T1 (de) * | 1999-03-30 | 2006-07-15 | Novartis Pharma Gmbh | Phthalazinderivate zur behandlung von entzündlicher erkrankungen |
| AR025068A1 (es) * | 1999-08-10 | 2002-11-06 | Bayer Corp | Pirazinas sustituidas y piridazinas fusionadas, composicion farmaceutica que las comprenden, uso de dichos compuestos para la manufactura de un medicamentocon actividad inhibidora de angiogenesis |
| EP1246617B1 (en) * | 1999-12-06 | 2006-09-13 | Rhode Island Hospital | Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of ovarian cancer |
-
2003
- 2003-09-23 CN CNB038227118A patent/CN100372535C/zh not_active Expired - Fee Related
- 2003-09-23 EP EP03798175A patent/EP1545534B1/en not_active Expired - Lifetime
- 2003-09-23 MX MXPA05003161A patent/MXPA05003161A/es active IP Right Grant
- 2003-09-23 KR KR1020057004971A patent/KR20050074450A/ko not_active Ceased
- 2003-09-23 ES ES03798175T patent/ES2285251T3/es not_active Expired - Lifetime
- 2003-09-23 HR HR20050281A patent/HRP20050281A2/xx not_active Application Discontinuation
- 2003-09-23 CA CA002499738A patent/CA2499738A1/en not_active Abandoned
- 2003-09-23 WO PCT/EP2003/010578 patent/WO2004028542A1/en not_active Ceased
- 2003-09-23 JP JP2004538994A patent/JP2006502195A/ja active Pending
- 2003-09-23 PT PT03798175T patent/PT1545534E/pt unknown
- 2003-09-23 US US10/528,914 patent/US20060128716A1/en not_active Abandoned
- 2003-09-23 DE DE60313344T patent/DE60313344T2/de not_active Expired - Lifetime
- 2003-09-23 RS YUP-2005/0228A patent/RS20050228A/sr unknown
- 2003-09-23 BR BR0314647-2A patent/BR0314647A/pt not_active IP Right Cessation
- 2003-09-23 RU RU2005112711/14A patent/RU2353364C2/ru not_active IP Right Cessation
- 2003-09-23 PL PL03374696A patent/PL374696A1/xx not_active Application Discontinuation
- 2003-09-23 AT AT03798175T patent/ATE359789T1/de not_active IP Right Cessation
- 2003-09-23 AU AU2003299065A patent/AU2003299065B2/en not_active Ceased
-
2005
- 2005-03-16 ZA ZA200502212A patent/ZA200502212B/en unknown
- 2005-03-17 CR CR7754A patent/CR7754A/es not_active Application Discontinuation
- 2005-03-23 EC EC2005005700A patent/ECSP055700A/es unknown
- 2005-04-20 NO NO20051936A patent/NO20051936L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200502212B (en) | 2006-02-22 |
| DE60313344D1 (de) | 2007-05-31 |
| WO2004028542A1 (en) | 2004-04-08 |
| EP1545534A1 (en) | 2005-06-29 |
| US20060128716A1 (en) | 2006-06-15 |
| CA2499738A1 (en) | 2004-04-08 |
| AU2003299065B2 (en) | 2006-10-26 |
| RU2005112711A (ru) | 2006-02-27 |
| JP2006502195A (ja) | 2006-01-19 |
| CN100372535C (zh) | 2008-03-05 |
| ES2285251T3 (es) | 2007-11-16 |
| ECSP055700A (es) | 2005-08-11 |
| PT1545534E (pt) | 2007-06-22 |
| KR20050074450A (ko) | 2005-07-18 |
| HRP20050281A2 (en) | 2006-07-31 |
| CN1684684A (zh) | 2005-10-19 |
| BR0314647A (pt) | 2005-08-02 |
| ATE359789T1 (de) | 2007-05-15 |
| RS20050228A (sr) | 2007-08-03 |
| NO20051936L (no) | 2005-06-23 |
| DE60313344T2 (de) | 2008-01-03 |
| RU2353364C2 (ru) | 2009-04-27 |
| AU2003299065A1 (en) | 2004-04-19 |
| EP1545534B1 (en) | 2007-04-18 |
| CR7754A (es) | 2005-12-02 |
| PL374696A1 (en) | 2005-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1339458B1 (en) | Combination comprising an agent decreasing vegf activity and an agent decreasing egf activity | |
| TW202345844A (zh) | 利用ｍｔａ協作的ｐｒｍｔ５抑制劑的癌症治療 | |
| AU2010247397B2 (en) | Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound | |
| NZ550174A (en) | Combinations comprising a vasculostatic compound such as vatalanib and epothilones, and pharmaceutical uses thereof | |
| US20060111358A1 (en) | Treatment of aml | |
| MXPA04006822A (es) | Combinaciones que comprenden epotilonas y anti-metabolitos. | |
| MXPA06002393A (es) | Tratamiento de cancer con epotilomas. | |
| AU2003299065B2 (en) | Use of 4-pyridylmethyl-phthalazine derivatives for the manufacture of a medicament for the treatment of myelodysplastic syndromes | |
| JP2009292837A (ja) | より効能が大きく副作用の少ない癌治療方法 | |
| US20080090848A1 (en) | Substituted Purinyl Derivatives With Immunomodulator And Chemoprotective Activity And Use Alone Or With Medium-Chain Length Fatty Acids Or Glycerides | |
| US8124593B2 (en) | Methods of treatment using sapacitabine | |
| JP2003055208A (ja) | 組み合わせ化学療法 | |
| US20090233939A1 (en) | Treatment of amm | |
| US11957701B2 (en) | Therapy and new therapeutic agent for blood cancer | |
| HK40121791A (en) | Cancer treatments using mta-cooperative prmt5 inhibitors | |
| AU2008203233B2 (en) | Combinations comprising epothilones and pharmaceutical uses thereof | |
| JP2006502195A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |